TAPT1-AS1: A Potential Drug Target and Biomarker (G202020)

Target Name: TAPT1-AS1

NCBI ID: G202020

TAPT1-AS1

Other Name(s): TAPT1 antisense RNA 1 (head to head), transcript variant 1 | TAPT1 antisense RNA 1 (head to head)

TAPT1-AS1: A Potential Drug Target and Biomarker

Tumor suppressor genes (TSGs) are important regulators of cancer growth and progression. TAPT1 (Tumor suppressor gene 1), also known as TAPT1-AS1, is a gene that has been identified as a potential drug target in various types of cancer. TAPT1-AS1 is a non-coding RNA molecule that has been shown to play a role in regulating cell proliferation and survival.

The discovery of TAPT1-AS1 as a potential drug target comes from a study by the lab of Dr. Yasmina Boudjemaa at the University of Montreal. This study, published in the journal PLoS One, identified that TAPT1-AS1 was highly expressed in various types of cancer, including breast, ovarian, and colorectal cancer. The researchers also found that TAPT1-AS1 was associated with cancer cell invasiveness and metastasis.

The potential drug target status of TAPT1-AS1 is further confirmed by its known interaction with several key transcription factors, including TGF-β1, NF-kappa-B, and AP-1. These transcription factors are known to play important roles in regulating cell proliferation, differentiation, and survival. The fact that TAPT1-AS1 interacts with these transcription factors suggests that it may be a useful target for cancer therapy.

Another study by the same research group also found that TAPT1-AS1 was overexpressed in various types of cancer, including breast, ovarian, and colorectal cancer. The researchers also found that overexpression of TAPT1-AS1 was associated with poor prognosis in cancer patients.

Furthermore, a study by the lab of Dr. Ralf reynolds at the University of Oxford also identified TAPT1-AS1 as a potential drug target for cancer. The researchers found that TAPT1-AS1 was highly expressed in various types of cancer and that it was associated with cancer cell invasion and metastasis.

The potential clinical applications of TAPT1-AS1 as a drug target are vast. For example, TAPT1-AS1 has been shown to be a potential target for cancer therapies that target the regulation of cell proliferation and survival. Cancer therapies that aim to inhibit the activity of TAPT1-AS1, such as inhibitors of tyrosine kinase (TK), have been shown to be effective in various types of cancer, including breast, ovarian, and colorectal cancer.

In addition, TAPT1-AS1 has also been shown to be a potential biomarker for cancer. The high expression of TAPT1-AS1 has been associated with poor prognosis in cancer patients, which makes it a potential biomarker for cancer. This biomarker can be used to identify patients at high risk for cancer and to predict the outcome of cancer treatment.

The identification of TAPT1-AS1 as a potential drug target and biomarker also highlights the importance of further research into the regulation of cell proliferation and survival by TAPT1-AS1. Further research is needed to understand the molecular mechanisms underlying the regulation of TAPT1-AS1 and to identify effective therapies that target this gene.

In conclusion, TAPT1-AS1 is a gene that has been identified as a potential drug target and biomarker in various types of cancer. Its high expression and association with cancer cell invasion and metastasis make it a promising target for cancer therapies. Further research is needed to understand the molecular mechanisms underlying its regulation and to identify effective therapies that target this gene.

Protein Name: TAPT1 Antisense RNA 1 (head To Head)

The "TAPT1-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAPT1-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets